Who are losers from the COVID-19 vaccine?
A return to normality thanks to a COVID-19 vaccine will highlight those stocks where valuations have been overdone in recent months and could see them struggle.
These would be healthcare stocks which had been providing PPE equipment and ventilators for the outbreak and online shopping, which would lose out as people returned to bricks-and-mortar retail.
Tech disrupters which been rising in share price in expectation of future profits from a digital and contactless COVID-19 world would also be hindered.
AMP Capital Australian equities portfolio manager, Dermot Ryan, said: “With the shift of earnings growth back into real businesses, some of these growth valuations are hard to justify and may push valuation multiples lower as the rate of change of customer adoption turns negative.
“The run up in valuations in tech has been overdone and there are real risks to their stock prices here if revenue trends moderate.”
A vaccine would also inoculate inflation and boost growth which would prompt a rotation of investment out of bonds and into equities that were reasonably valued.
Winners from the vaccine would be travel, energy and banking as they had struggled during the pandemic from factors such as border restrictions, lack of energy demand and weak commodity prices.
“These three poster child value sectors are now so cheap that they might offer high earnings per share growth, as much lower valuations than you can get in the growth side of the market and that is why they can make sustained gains as the virus is forced to retreat.”
AUTHOR
Laura Dew
Recommended for you
Clime Investment Management has faced shareholder backlash around “unsatisfactory” financial results and is enacting cost reductions to return the business to profitability by Q1 2025.
Amid a growing appetite for alternatives, investment executives have shared questions advisers should consider when selecting a private markets product compared to their listed counterparts.
Chief executive Maria Lykouras is set to exit JBWere as the bank confirms it is “evolving” its operations for high-net-worth clients.
Bennelong Funds Management chief executive John Burke has told Money Management that the firm is seeking to invest in boutiques in two specific asset classes as it identifies gaps in its product range.
